

**Whipple Family Limited Partnership; Acquisition of Company Engaged in Permissible Nonbanking Activities**

The organization listed in this notice has applied under § 225.23(a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 31, 1995.

**A. Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Whipple Family Limited Partnership*, Arkadelphia, Arkansas; to acquire First Banc Securities, Inc., Arkadelphia, Arkansas, and thereby provide portfolio investment advice and engage in securities brokerage activities, pursuant to §§ 225.25(b)(4) and 225.25(b)(15) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, January 10, 1995.

**Jennifer J. Johnson**,  
*Deputy Secretary of the Board.*

[FR Doc. 95-1022 Filed 1-13-95; 8:45 am]

BILLING CODE 6210-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Agency for Health Care Policy and Research**

**Notice of Meeting**

In accordance with section 10(a) of the Federal Advisory Committee Act (Title 5, U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of January 1995:

Name: Health Care Policy and Research Special Emphasis Panel.

Date and Time: January 12, 1995 8:30 a.m.  
Place: Holiday Inn Crowne Plaza, 1750 Rockville Pike, Woodmont Room, Rockville, Maryland 20852.

Open January 12, 8:30 a.m. to 9:00 a.m.  
Closed for remainder of meeting.

Purpose: This Panel is charged with conducting the initial review of grant applications on research related to care for persons with acquired immune deficiency syndrome (AIDS) and other related human immunodeficiency virus (HIV) diseases.

Agenda: The open session of the meeting on January 12 from 8:30 a.m. to 9:00 a.m. will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing grant applications dealing with 1) cost and financing of HIV/AIDS treatments and services; 2) organization and delivery of services; 3) characteristics and interactions of providers and patients; 4) comorbidity; and 5) special populations.

In accordance with the Federal Advisory Committee Act, Title 5, U.S.C., Appendix 2 and Title 5, U.S.C., 552b(c)(6), the Administrator, AHCPHR, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Gerald E. Calderone, Ph.D., Agency for Health Care Policy and Research, Suite 602, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594-2462.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: January 4, 1995.

**Linda K. Demlo**,  
*Acting Administrator.*

[FR Doc. 95-1075 Filed 1-13-95; 8:45 am]

BILLING CODE 4160-90-P

**Food and Drug Administration**

[Docket No. 94N-0304]

**Sandoz Pharmaceuticals Corp.; Bromocriptine Mesylate (Parlodel); Withdrawal of Approval of the Indication for the Prevention of Physiological Lactation**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of those parts of the new drug application (NDA) 17-962, for Parlodel (bromocriptine mesylate) that pertain to the prevention of physiological lactation. NDA 17-962 is held by Sandoz Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936 (Sandoz). The basis for the action is a reevaluation finding that bromocriptine is not shown to be safe for use in the prevention of physiological lactation. Sandoz has waived its opportunity for a hearing. No other party has requested a hearing within the 30 days after the date of publication of the notice in the **Federal Register** of August 23, 1994.

**EFFECTIVE DATE:** February 16, 1995.

**FOR FURTHER INFORMATION CONTACT:** Harry Schiller, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of August 23, 1994 (59 FR 43347), the Director of the Center for Drug Evaluation and Research (the Director) offered an opportunity for a hearing on a proposal to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) to withdraw approval of Parlodel's approved indication pertaining to the prevention of postpartum physiological lactation. The basis for the proposed action was a reevaluation finding that bromocriptine is no longer shown to be safe for this indication. Interested parties were given 30 days to give a request for an opportunity for a hearing. Subsequently, Sandoz, the holder of NDA 17-962, in a letter dated August 23, 1994, waived its opportunity for a hearing. No other party has filed a request for a hearing within the 30 days after the date of publication of the notice in **Federal Register** of August 23, 1994.

Accordingly, for the reasons discussed in the August 23, 1994, notice, the Director, under section 505(e) of the act, and under authority